Logan Capital Management Inc Gilead Sciences, Inc. Transaction History

Logan Capital Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$71.58 - $87.29 $143 - $174	2 Added 0.05%	4,204 $307,000
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $14,800 - $16,784	202 Added 5.05%	4,202 $340,000
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $3,105 - $3,904	-50 Reduced 1.23%	4,000 $253,000
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $3,617 - $4,200	50 Added 1.25%	4,050 $312,000
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $12,350 - $16,116	-204 Reduced 4.85%	4,000 $250,000
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $10,264 - $11,364	144 Added 3.55%	4,204 $325,000
Q4 2017 Feb 12, 2018	SELL	$71.15 - $83.52 $4,269 - $5,011	-60 Reduced 1.46%	4,060 $291,000
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $3,821 - $4,529	53 Added 1.3%	4,120 $334,000
Q2 2017 Aug 14, 2017	BUY	N/A	4,067	4,067 $288,000

1,942

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $117B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Logan Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Logan Capital Management Inc with notifications on news.